CSL Behring's recently approved gene therapy for haemophilia B Hemgenix has joined the swelling ranks of new medicines that are bundled with a companion app to support the patients treated with them.

CSL Behring最近批准的血友病B Hemgenix基因治疗已加入与同伴应用捆绑在一起的新药肿胀队伍，以支持接受治疗的患者。

The B SUPPORT Patient app developed with companion app specialist BrightInsight is used to assess a patient's current treatment and the impact on their lives by tracking bleeds, Factor IX activity, and how they are feeling.

B支持患者应用程序由同伴应用程序专家BrightInsight开发，用于通过跟踪出血，IX因子活动以及他们的感受来评估患者当前的治疗方法及其对生活的影响。

It also guides them through the gene therapy procedure 'from eligibility to dosing to monitoring' and can be used to support patients as they make the transition from needing regular injections of Factor IX replacement therapies after the one-shot Hemgenix (etranacogene dezaparvovec) therapy.

它还指导他们通过基因治疗程序“从资格到剂量到监测”，并可用于支持患者，因为他们在一次性Hemgenix（etranacogene dezaparvovec）治疗后需要定期注射IX因子替代疗法。

Hemgenix was approved in the EU in February and in the US in June as the first gene therapy for adults with severe and moderately severe haemophilia B without a history of Factor IX inhibitors – antibodies that can develop in patients treated with replacement therapies.

Hemgenix于2月在欧盟和6月在美国被批准为成人重度和中度重度血友病B的第一种基因疗法，该疗法没有IX因子抑制剂的病史-可以在接受替代疗法治疗的患者中产生抗体。

In the HOPE-B trial, 96% of haemophilia B patients treated with a single infusion of the gene therapy had a sustained increase in Factor IX levels which meant they could discontinue Factor IX replacement, which was accompanied by a 64% reduction in bleed rates.

在HOPE-B试验中，96%接受单次输注基因治疗的B型血友病患者的IX因子水平持续升高，这意味着他们可以停止IX因子替代治疗，同时出血减少64%率。

'Transitioning to a one-time gene therapy is not a straight path – patients may be hesitant at trying a novel therapy,' said CSL and BrightInsight in a statement on the app's launch.

CSL和BrightInsight在应用程序推出的声明中说：“过渡到一次性基因治疗不是一条直线的道路-患者可能在尝试新疗法时犹豫不决。”。

The app can advise patients whether they are likely to be a candidate for Hemgenix, help them prepare for consultations with their doctors and access a CSL support team.

该应用程序可以告知患者他们是否可能成为Hemgenix的候选人，帮助他们准备与医生进行咨询并访问CSL支持团队。

'We worked closely with BrightInsight to develop an app that met the diverse needs of haemophilia B patients,' said David Chu, director of marketing for Hemgenix.

Hemgenix营销总监David Chu说：“我们与BrightInsight密切合作开发了一款满足B型血友病患者不同需求的应用程序。

'With CSL's deep market knowledge and long history serving this community and BrightInsight's astute understanding of patient needs and behaviours, we carefully studied the patient journey to identify touch points we could impact with digital. Together we were able to build tools that guided patients through this unique journey in a very holistic way.'.

“凭借CSL深入的市场知识和悠久的历史为这个社区服务，BrightInsight对患者需求和行为的敏锐理解，我们仔细研究了患者旅程，以确定我们可以通过数字影响的接触点。我们一起能够构建工具，以非常全面的方式指导患者完成这一独特的旅程。

Future releases of the app will include additional community-focused features and support for more languages, including content and features for users earlier in the consideration phase who may not yet be aware of gene therapy as a treatment option.

该应用程序的未来版本将包括其他以社区为中心的功能，并支持更多语言，包括考虑阶段早期用户的内容和功能，这些用户可能尚未意识到基因治疗是一种治疗选择。

This is the second companion app developed by BrightInsight to support a CSL product after the two companies forged a digital health alliance in 2020. The first was introduced to assist patients taking Hizentra (human immune globulin) product for primary immune deficiency.

这是BrightInsight在2020年两家公司建立数字健康联盟后开发的第二个配套应用程序，用于支持CSL产品。第一个是为了帮助患者服用Hizentra（人类免疫球蛋白）产品治疗原发性免疫缺陷。